Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

globenewswire.com
AMGN Amgen is listed as a key player in the growing anti-cancer MAbS market, indicating potential but without specific positive or negative news in the article. BMY Bristol Myers Squibb is identified as a key player in the expanding anti-cancer MAbS market, suggesting relevance but no specific sentiment is conveyed. LLY Eli Lilly and Company is named as a key player in the anti-cancer MAbS market, which is experiencing growth, but the article provides no specific sentiment for the company. JNJ Johnson & Johnson is listed as a key player in the anti-cancer MAbS market, which is projected to grow, but the article does not offer specific sentiment for the company. PFE Pfizer is mentioned as a key player in the growing anti-cancer MAbS market. The article provides no specific positive or negative sentiment for the company. MRK Merck's acquisition of Prometheus Biosciences is mentioned, expanding its portfolio in precision immunology, which is a positive development within the growing oncology market. ZWS Zymeworks Inc. is named among leading companies in the anti-cancer MAbS market, indicating its presence in a growing sector, but no specific sentiment is provided.

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The anti-cancer monoclonal antibodies (mAbs) market has recently experienced robust growth, expanding from $71.25 billion in 2025 to $78.12 billion in 2026, reflecting a CAGR of 9.6%. This growth is driven by the increasing cancer incidence worldwide, successful clinical trials, investments in oncology R&D, regulatory approvals, and better survival outcomes in cancer therapies.

Projections suggest the market will maintain its upward trajectory, reaching $112.41 billion by 2030 with a CAGR of 9.5%. The future growth will be fueled by advancements in personalized cancer medicine, the rise of biosimilar mAbs, increased healthcare spending in oncology, and breakthroughs in antibody engineering. Trends shaping the market include the adoption of targeted immunotherapies, the development of humanized and bispecific antibodies, and a focus on precision oncology.

Cancer prevalence continues to bolster demand for anticancer mAbs, with factors like aging demographics, lifestyle changes, and advanced diagnostics contributing to higher detection rates. The WHO predicts more than 35 million new cancer cases by 2050, a significant increase from 2022's estimated 20 million, propelling market growth.

Leading companies such as Y-mAbs Therapeutics and Merck & Co., Inc. are exploring novel therapeutic approaches. Y-mAbs has initiated a Phase I trial for GD2-SADA, a radioimmunotherapy targeting GD2-positive tumors, while Merck's acquisition of Prometheus Biosciences expands its portfolio in precision immunology.

Key players in the anti-cancer mAbs market include Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company, Roche, GlaxoSmithKline, Johnson & Johnson, Novartis, and Pfizer, among others. Regionally, North America leads the market as of 2025, with Asia-Pacific poised for the fastest growth. Countries such as the USA, China, and Japan are pivotal in this market's development.

Report Scope

This report tackles pivotal questions such as the identification of largest and most rapidly growing markets for anti-cancer MAbS, its correlation with broader economic and market trends, and factors influencing its trajectory. Coverage includes market characteristics, size, segmentation, regional and country-specific analysis, TAM, MAS, competitive landscape, market shares, company scoring, and strategic trends.

Markets Covered:

Subsegments further categorize antibody types and market applications. The report also names leading companies, from Amgen Inc. to Zymeworks Inc., providing a detailed competitive landscape.

Countries covered include major markets like the USA, UK, China, and India, with regional focuses on Asia-Pacific, North America, and more. The time series covers five-year historical data with a ten-year forecast, offering an extensive analytical window.

Data Segmentation: Across geographies, segment-wise data, and competitor market share.

Key Attributes

The companies featured in this Anti-Cancer MAbS market report include:

For more information about this report visit https://www.researchandmarkets.com/r/omdieb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment